Skyrizi 360 MG/2.4 ML on-body 2.4ML
Ended Awarded Last action
- Contract number
- SPE2DR26F9MS1
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $12,467
Award facts
- Contract value 100% obligated
- $12,467.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $12,467 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of SKYRIZI 360 mg/2.4 mL on-body injection units. The contract, awarded on January 23, 2026, with a completion date of February 13, 2026, represents a task order under AmerisourceBergen's parent company Cencora, Inc.'s existing Indefinite Delivery Contract with DLA Troop Support Medical. This IDC, valued at up to $999.99 million through December 2031, serves as the primary vehicle for delivering a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The award was not set-aside and was competitively awarded, indicating AmerisourceBergen's capability to meet federal procurement requirements in open competition.
SKYRIZI is a biologic medication used to treat autoimmune inflammatory conditions, and this delivery order fulfills DLA's requirement to maintain adequate pharmaceutical inventory for military treatment facilities and veterans' healthcare programs. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement and demonstrates consistent capability in delivering specialized pharmaceutical products across multiple therapeutic domains. The firm fixed-price structure ensures cost predictability for the government while leveraging the broader IDC framework that enables efficient, flexible sourcing of essential medical commodities to support military healthcare operations.
Quick answers
Who was awarded contract SPE2DR26F9MS1?
SPE2DR26F9MS1 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 23, 2026.
How much is contract SPE2DR26F9MS1 worth?
The government has obligated $12,467 on SPE2DR26F9MS1.
Is contract SPE2DR26F9MS1 an order under another contract?
Yes. SPE2DR26F9MS1 is a delivery order under SPE2DR25D2206, an indefinite delivery contract.
Was contract SPE2DR26F9MS1 competed?
The extent of competition for SPE2DR26F9MS1 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award